Tenax Therapeutics, Inc.
TENXTenax Therapeutics, Inc. is a pharmaceutical company focused on developing targeted therapies for critical and serious respiratory and cardiovascular conditions. It is known for its development of inhaled drugs designed to improve outcomes for patients with pulmonary hypertension and other life-threatening diseases. The company's pipeline emphasizes innovative solutions to address unmet medical needs in these areas.
Company News
Tenax Therapeutics will participate in the Cantor Global Healthcare Conference 2025, presenting a fireside chat about their ongoing Phase 3 LEVEL Study for pulmonary hypertension treatment, with patient enrollment expected in first half of 2026.
The global plastic fencing market is expected to grow significantly due to rising demand from the residential and commercial construction industries, as well as the increasing adoption of recycled plastics in fencing products.
Tenax Therapeutics, a Phase 3 pharmaceutical company, announced its participation in the Guggenheim SMID Cap Biotech Conference, where its President and CEO will present in a fireside chat.
The White House has ordered a temporary freeze on all federal grants and loans, putting $3 trillion in funding under scrutiny and threatening industries like clean energy, defense, and healthcare.
The article discusses the evolving landscape of rare cardiovascular diseases, including Giant-Cell Arteritis, Pulmonary Arterial Hypertension, and Restrictive Cardiomyopathy. It highlights the challenges in diagnosis and treatment, as well as the growing market size and pipeline of new therapies for these conditions.
Related Companies
